Dr Agarwal’s Health Care Mar 2026: The 115x P/E Optical Illusion

Section 1 — At a Glance

A multi-year capital deployment cycle has brought Dr Agarwal’s Health Care Limited to an operating inflection point, marked by cross-network scale expansion and structural changes to its structural asset base. Total consolidated income for FY26 reached ₹2,125 crore, driven by high-volume clinical conversions and an intentional pivot toward premium surgical modalities. However, the aggressive rollout of greenfield infrastructure continues to exert a meaningful drag on current-period returns, keeping the company’s Return on Equity pinned at a modest 6.81% for the year.

Investor attention is increasingly focused on the friction between rapid hospital network scaling and near-term capital efficiency metrics. The company capitalized on a significant equity infusion to re-engineer its capital structure, bringing external borrowings excluding lease obligations down to ₹179.8 crore by mid-FY26. Yet, the persistent drag from newer cluster territories stands out as a clear operational risk, directly impacting overall earnings quality.

When structural expansion velocity outpaces immediate asset optimization, asset utilization curves will look underwhelming before they turn rewarding. The imminent integration of its listed corporate arm presents a clear step toward operating simplification, though structural overheads remain structurally locked.

Section 2 — Introduction

Dr Agarwal’s Health Care Limited is currently staging an ambitious corporate land grab disguised as an eye care chain rollout. This is a business where growth does not mean building an entirely new corporate campus from scratch every time. Instead, management leases a retail space, populates it with complex ophthalmic diagnostic gear, and begins looking for patients. While the medical delivery is highly technical, the capital allocation playbook operates like an absolute land grab strategy.

Section 3 — Business Model: WTF Do They Even Do?

The core engine runs on a classic hub-and-spoke model. The “spokes” are non-surgical primary clinics designed to capture walk-ins and forward complex refractive or retinal distress upstream. The “hubs” are specialty surgical centers doing the heavy lifting.

Surgeries bring in 66.7% of the top line, while optical frames, lenses, and eye drops account for the remaining 33.3% of business activity. It is an asset-light framework because they do not buy real estate. Instead, they lease almost everything, keeping upfront capital expenditure minimal and ensuring faster branch-level stabilization timelines.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

The business displays stable seasonal dynamics, with the final quarter of the fiscal year emerging as the most productive. Volume momentum is supported by cross-network patient walk-ins expanding toward 10,000 per day.

What is Management Promising in the Coming Quarters?

Management expects organic expansion to continue at a regular weekly cadence. Forward capital spending is guided at ₹380 to ₹400 crore for the next fiscal period, targeting a step-up to 60 new facility openings divided equally across both halves of the year. The focus is expanding beyond southern strongholds, with West and North India additions guided to double their absolute footprint over the coming fiscal cycle. Management expects underlying operating leverage to absorb upfront branch start-up outlays, preserving structural margins.

Section 5 — Valuation Discussion: Fair Value Range Only

To map out the company’s